Related Experiment Video
Updated: Jan 25, 2026

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture
Published on: August 4, 2023
Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis
Nathan P Wiederhold1, Laura Kovanda2, Laura K Najvar3
1University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA wiederholdn@uthscsa.edu.
Abstract:
We evaluated the efficacy of isavuconazole against cryptococcal meningitis. Treatment with either oral isavuconazole (120 mg/kg and 240 mg/kg twice a day [BID]) or fluconazole as the positive control significantly improved survival in mice infected intracranially with either Cryptococcus neoformans USC1597 or H99 and significantly reduced brain fungal burdens for both isolates. Concentrations of isavuconazole in plasma and brain tissue also demonstrated that the greatest improvements in survival and fungal burden were associated with elevated exposures.
Insights
Isavuconazole significantly improved survival and reduced fungal burden in mice with cryptococcal meningitis. Higher drug exposures correlated with greater treatment efficacy against Cryptococcus neoformans.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Cryptococcal meningitis remains a significant global health threat, particularly in immunocompromised individuals.
- Limited treatment options and emerging resistance necessitate the development of novel antifungal therapies.
- Isavuconazole is a broad-spectrum triazole antifungal with demonstrated activity against various fungal pathogens.
Purpose of the Study:
- To evaluate the efficacy of isavuconazole in a murine model of cryptococcal meningitis.
- To compare the therapeutic effects of isavuconazole with fluconazole, a standard antifungal treatment.
- To investigate the relationship between isavuconazole exposure levels and treatment outcomes.
Main Methods:
- Infection of mice with Cryptococcus neoformans (strains USC1597 and H99) via intracranial inoculation.
- Administration of oral isavuconazole at two different doses (120 mg/kg BID and 240 mg/kg BID) or fluconazole (positive control).
- Assessment of survival rates and quantification of fungal burden in brain tissue post-treatment.
Main Results:
- Both isavuconazole doses and fluconazole significantly improved survival rates in infected mice.
- Isavuconazole treatment led to a significant reduction in fungal burden in the brain for both C. neoformans isolates.
- Elevated plasma and brain tissue concentrations of isavuconazole were associated with enhanced survival and reduced fungal loads.
Conclusions:
- Isavuconazole demonstrates significant efficacy against experimental cryptococcal meningitis caused by C. neoformans.
- The drug offers a promising therapeutic option for cryptococcal meningitis, with dose-dependent improvements in outcomes.
- Further clinical investigation of isavuconazole for cryptococcal meningitis is warranted.
Related Concept Videos
Cranial and Spinal Meninges
Cranial Meninges
These meningeal layers cover the cranium. The dura mater is the outermost layer of cranial meninges. It is a thick and durable membrane of dense...
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects
Biological Effects of Radiation
Experimental Determination of Chemical Formula
Experimental Designs

